A-Kinase Interacting Protein 1 与多发性骨髓瘤患者临床特征、治疗反应和生存状况的相关性。
Correlation of A-Kinase Interacting Protein 1 With Clinical Features, Treatment Response, and Survival Profiles in Patients With Multiple Myeloma.
机构信息
Department of Hematology, 159397Huashan Hospital, Fudan University, Shanghai, China.
Department of Hematology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
出版信息
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820935856. doi: 10.1177/1533033820935856.
OBJECTIVE
The present study aimed to detect A-kinase interacting protein 1 expression and further explore the association of A-kinase interacting protein 1 with clinical features and prognosis in patients with multiple myeloma.
METHODS
Totally, 152 symptomatic patients with multiple myeloma and 30 healthy donors were enrolled. Bone marrow mononuclear cells derived plasma cells were collected from patients with multiple myeloma before initial treatment and from healthy donors on the enrollment, respectively, and then A-kinase interacting protein 1 protein/messenger RNA expressions were detected by Western blot and reverse transcription quantitative polymerase chain reaction. Treatment response (complete response and overall response rate) was assessed, and survival profiles (progression-free survival and overall survival) were calculated in patients with multiple myeloma.
RESULTS
A-kinase interacting protein 1 protein/messenger RNA expressions were elevated in patients with multiple myeloma compared to healthy donors, and A-kinase interacting protein 1 (area under the curve: 0.809, 95% confidence interval: 0.726-0.891)/messenger RNA (area under the curve: 0.839, 95% confidence interval: 0.764-0.914) presented good value in differentiating patients with multiple myeloma from healthy donors. In patients with multiple myeloma, A-kinase interacting protein 1 /messenger RNA expressions negatively correlated with albumin while positively correlated with Beta-2-microglobulin, lactate dehydrogenase, International Staging System stage, and t (4;14). Meanwhile, there were 39 (25.7%) complete response patients, 113 (74.3%) noncomplete response patients, 112 (73.7%) overall response rate patients, and 40 (26.3%) nonoverall response rate patients. Complete response and overall response rates were decreased in patients with high A-kinase interacting protein 1 compared to patients with low A-kinase interacting protein 1. Additionally, progression-free survival and overall survival were reduced in patients with high A-kinase interacting protein 1 compared to patients with low A-kinase interacting protein 1.
CONCLUSION
A-kinase interacting protein 1 exhibits the potency as a biomarker for multiple myeloma progression and prognosis, which implies the clinical application of A-kinase interacting protein 1 in multiple myeloma management.
目的
本研究旨在检测 A-激酶相互作用蛋白 1 的表达，并进一步探讨 A-激酶相互作用蛋白 1 与多发性骨髓瘤患者临床特征和预后的关系。
方法
共纳入 152 例有症状的多发性骨髓瘤患者和 30 名健康供者。分别从多发性骨髓瘤患者初治前和健康供者入组时采集骨髓单个核细胞来源的浆细胞，通过 Western blot 和逆转录定量聚合酶链反应检测 A-激酶相互作用蛋白 1 蛋白/信使 RNA 的表达。评估多发性骨髓瘤患者的治疗反应（完全缓解和总缓解率），并计算生存情况（无进展生存期和总生存期）。
结果
与健康供者相比，多发性骨髓瘤患者的 A-激酶相互作用蛋白 1 蛋白/信使 RNA 表达升高，A-激酶相互作用蛋白 1（曲线下面积：0.809，95%置信区间：0.726-0.891）/信使 RNA（曲线下面积：0.839，95%置信区间：0.764-0.914）在区分多发性骨髓瘤患者和健康供者方面具有良好的价值。在多发性骨髓瘤患者中，A-激酶相互作用蛋白 1/信使 RNA 表达与白蛋白呈负相关，与β2-微球蛋白、乳酸脱氢酶、国际分期系统分期和 t（4；14）呈正相关。同时，有 39 例（25.7%）患者达到完全缓解，113 例（74.3%）患者未达到完全缓解，112 例（73.7%）患者总缓解率，40 例（26.3%）患者总缓解率。与 A-激酶相互作用蛋白 1 低表达的患者相比，A-激酶相互作用蛋白 1 高表达的患者完全缓解率和总缓解率较低。此外，与 A-激酶相互作用蛋白 1 低表达的患者相比，A-激酶相互作用蛋白 1 高表达的患者无进展生存期和总生存期较短。
结论
A-激酶相互作用蛋白 1 作为多发性骨髓瘤进展和预后的生物标志物具有潜力，提示 A-激酶相互作用蛋白 1 在多发性骨髓瘤治疗中的临床应用。
Zotero 插件